Anne-Marie Leiby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anne-Marie Leiby has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Seyed Ahmad Sajjadi
Department of Neurology, University of California, Irvine, CA, USA
4 shared publications Aanan Ramanathan
Department of Neurology, University of California, Irvine, CA, USA
1 shared publicationChu-Ching Ho
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA
1 shared publication- Claudia H. Kawas
Department of Neurobiology and Behavior, University of California, Irvine
1 shared publication Farheen Basith
University of California Irvine, Irvine, CA USA
1 shared publicationGhazaleh Ahmadi Jazi
Department of Neurology, University of California, Irvine, CA, USA
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Characteristics of oldest‐old individuals with ‘Pure’ Limbic‐predominant age‐related TDP‐43 encephalopathy: a 90+ Study case series
Background: Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is an important contributor to dementia at age 90+. Given the high prevalence of multiple pathologies in the oldest old, the prevalence of ‘pure’ LATE and its clinical and cognitive features are poorly understood. The aims of this report are: (1) to determine the prevalence of ‘pure’ LATE among participants of The 90+ Study and (2) to describe clinical and cognitive features of ‘pure’ LATE.Method: Individuals for this report were identified from a total of 364 consecutive autopsies of The 90+ Study . We compared medical histories and cognition in three groups: those with ‘pure’ LATE, ‘pure’ Alzheimer’s disease neuropathologic change (ADNC), and ‘pure’ primary age‐related tauopathy (PART). ‘Pure’ LATE was defined as TDP‐43 in the hippocampus or neocortex, no moderate/severe ADNC, and no limbic/cortical Lewy bodies. ‘Pure’ ADNC group was defined as moderate/severe ADNC, no TDP‐43, and no limbic/cortical Lewy bodies. ‘Pure’ PART group was defined as limbic/cortical phosphorylated tau inclusions (Braak tau stage ≥2), no amyloid (A score = 0 and C score = 0), no TDP‐43, and no limbic/cortical Lewy bodies. All groups had <2 microvascular lesions.Result: LATE pathology was prevalent in the cohort (36%) but only 5 participants (1.4%) had ‘pure’ LATE. ‘Pure’ LATE group was on average older at death, more educated, and had lower proportion of women (Table) compared to the other two groups. Duration of cognitive impairment was longest and dementia was more prevalent in ‘pure’ LATE (6 years, 80%) compared to ‘pure’ ADNC (3 years, 43%) and ‘pure’ PART (3 years, 22%). Memory and executive function were more frequently impaired in ‘pure’ LATE compared to the other two groups (Table). Furthermore, histories of cardiovascular disease, syncope, depression, and extrapyramidal signs were more common, whereas osteoarthritis was less common, in ‘pure’ LATE compared to the other two groups (Table).Conclusion: Given the high prevalence of multiple pathologies, ‘pure’ LATE is a relatively rare finding in the oldest old. Identifying differences between ‘pure’ LATE and other dementia related neuropathologies in this case series, may provide valuable insight to inform proper ante‐mortem diagnosis of LATE.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessCharacteristics of oldest‐old individuals with ‘Pure’ Limbic‐predominant age‐related TDP‐43 encephalopathy: a 90+ Study case series
Background: Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is an important contributor to dementia at age 90+. Given the high prevalence of multiple pathologies in the oldest old, the prevalence of ‘pure’ LATE and its clinical and cognitive features are poorly understood. The aims of this report are: (1) to determine the prevalence of ‘pure’ LATE among participants of The 90+ Study and (2) to describe clinical and cognitive features of ‘pure’ LATE.Method: Individuals for this report were identified from a total of 364 consecutive autopsies of The 90+ Study . We compared medical histories and cognition in three groups: those with ‘pure’ LATE, ‘pure’ Alzheimer’s disease neuropathologic change (ADNC), and ‘pure’ primary age‐related tauopathy (PART). ‘Pure’ LATE was defined as TDP‐43 in the hippocampus or neocortex, no moderate/severe ADNC, and no limbic/cortical Lewy bodies. ‘Pure’ ADNC group was defined as moderate/severe ADNC, no TDP‐43, and no limbic/cortical Lewy bodies. ‘Pure’ PART group was defined as limbic/cortical phosphorylated tau inclusions (Braak tau stage ≥2), no amyloid (A score = 0 and C score = 0), no TDP‐43, and no limbic/cortical Lewy bodies. All groups had <2 microvascular lesions.Result: LATE pathology was prevalent in the cohort (36%) but only 5 participants (1.4%) had ‘pure’ LATE. ‘Pure’ LATE group was on average older at death, more educated, and had lower proportion of women (Table) compared to the other two groups. Duration of cognitive impairment was longest and dementia was more prevalent in ‘pure’ LATE (6 years, 80%) compared to ‘pure’ ADNC (3 years, 43%) and ‘pure’ PART (3 years, 22%). Memory and executive function were more frequently impaired in ‘pure’ LATE compared to the other two groups (Table). Furthermore, histories of cardiovascular disease, syncope, depression, and extrapyramidal signs were more common, whereas osteoarthritis was less common, in ‘pure’ LATE compared to the other two groups (Table).Conclusion: Given the high prevalence of multiple pathologies, ‘pure’ LATE is a relatively rare finding in the oldest old. Identifying differences between ‘pure’ LATE and other dementia related neuropathologies in this case series, may provide valuable insight to inform proper ante‐mortem diagnosis of LATE.
- 14 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Dementia Detection from Speech Using Machine Learning and Deep Learning Architectures.
This study focuses on using speech features to recognize dementia in patients. Previous studies have used speech features along with other linguistic features obtained from transcriptions, but this study explores using standalone speech features. The study utilizes speech samples from the Pitt corpus in the Dementia Bank and proposes a compact set of prosodic, voice quality, and cepstral speech features for the recognition task. The study uses machine learning (ML) and deep learning (DL) models and found that ML models performed better (87.6%) compared to DL models (85%). The results show that the proposed approach of using standalone speech features and ML models is promising for recognizing dementia with lower time and memory consumption compared to existing works.
- 14 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Dementia Detection from Speech Using Machine Learning and Deep Learning Architectures.
This study focuses on using speech features to recognize dementia in patients. Previous studies have used speech features along with other linguistic features obtained from transcriptions, but this study explores using standalone speech features. The study utilizes speech samples from the Pitt corpus in the Dementia Bank and proposes a compact set of prosodic, voice quality, and cepstral speech features for the recognition task. The study uses machine learning (ML) and deep learning (DL) models and found that ML models performed better (87.6%) compared to DL models (85%). The results show that the proposed approach of using standalone speech features and ML models is promising for recognizing dementia with lower time and memory consumption compared to existing works.
- 14 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
Limbic predominant age-related TDP-43 encephalopathy (LATE) is often comorbid with Alzheimer’s Disease (AD), and thus is it is difficult to disentangle the impact of LATE alone. This study aims to identify the clinical and cognitive features during baseline visit for LATE patients (n=31) and to compare these patients to those with AD (n=394) and with comorbid LATE + AD (n=262). This study’s participant data were from the National Alzheimer’s Coordination Center (NACC). Results from this study conclude that LATE patients lived longer, were older when cognitive decline started, and were more likely to be cognitively normal at first visit. LATE patients also reported fewer memory complaints than the AD or LATE+AD patients. For all neuropsychological tests, LATE+AD patients performed worse than the LATE and AD patients. While this study observed differences between the LATE, AD, and LATE+AD patients, future research is needed to identify further biomarkers for LATE.
- 14 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
Limbic predominant age-related TDP-43 encephalopathy (LATE) is often comorbid with Alzheimer’s Disease (AD), and thus is it is difficult to disentangle the impact of LATE alone. This study aims to identify the clinical and cognitive features during baseline visit for LATE patients (n=31) and to compare these patients to those with AD (n=394) and with comorbid LATE + AD (n=262). This study’s participant data were from the National Alzheimer’s Coordination Center (NACC). Results from this study conclude that LATE patients lived longer, were older when cognitive decline started, and were more likely to be cognitively normal at first visit. LATE patients also reported fewer memory complaints than the AD or LATE+AD patients. For all neuropsychological tests, LATE+AD patients performed worse than the LATE and AD patients. While this study observed differences between the LATE, AD, and LATE+AD patients, future research is needed to identify further biomarkers for LATE.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Prevalence of Autoantibody Positivity and Associated Neuropathologies in the Oldest-old (P3-6.009)
Objective: Our aim was to identify the prevalence of autoantibodies in an oldest-old cohort and to examine the relationship between presence of autoantibodies and neuropathologies found at postmortem. Background: Few studies have reported antibody prevalence in the oldest-old (age 90+). The association between autoantibody prevalence and presence of degenerative neuropathologies is yet to be studied. Design/Methods: Participants in an oldest old cohort (The 90+ Study) with at least one serum test result for antinuclear (ANA), antineutrophil cytoplasmic (ANCA), rheumatoid factor (RF), antithyroglobulin (ANTITG), and anti-double stranded DNA (DS-DNA) antibodies were examined. Test results were dichotomized (positive/negative). A subset had autopsy-confirmed neuropathology diagnosis for Alzheimer’s disease neuropathologic change, Lewy body disease, limbic-predominant age related TDP-43 encephalopathy, hippocampal sclerosis (HS), and aging-related tau astrogliopathy. We examined the relationship between neuropathology and antibody positivity using Fischer Chi-Square with Yates’ continuity correction. Results: Of 168 participants with serum results, 44% tested positive for ANA, 31% for ANCA, 21% for RF, 10% for ANTITG, and 6% for DS-DNA antibodies. In the subset with available postmortem results (N=19), antibody positivity rate was similar to the main cohort. Importantly, all participants with hippocampal sclerosis (N=4), were ANA positive and two (50%) had RF antibody. Also the single case with ANTITG antibody had HS. There were no other directions appearing from the other antibody and pathology results. Conclusions: We found that autoantibody positivity rate in an oldest old cohort was much higher than younger cohorts. Increased rate of autoimmunity is a potential explanation for this finding. Furthermore, all individuals with autopsy confirmed HS were ANA positive. In addition, half of HS cases had RF positivity and the only ANTITG positive case had HS. These results raise the possibility of an autoimmune etiology for this common degenerative pathology. Disclosure: Miss Leiby has nothing to disclose. Mr. Ramanathan has nothing to disclose. Ms. Ho has nothing to disclose. Mr. Siguenza has nothing to disclose. Dr. Ahmadi Jazi has nothing to disclose. The institution of Dr. Sajjadi has received research support from NIH.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Prevalence of Autoantibody Positivity and Associated Neuropathologies in the Oldest-old (P3-6.009)
Objective: Our aim was to identify the prevalence of autoantibodies in an oldest-old cohort and to examine the relationship between presence of autoantibodies and neuropathologies found at postmortem. Background: Few studies have reported antibody prevalence in the oldest-old (age 90+). The association between autoantibody prevalence and presence of degenerative neuropathologies is yet to be studied. Design/Methods: Participants in an oldest old cohort (The 90+ Study) with at least one serum test result for antinuclear (ANA), antineutrophil cytoplasmic (ANCA), rheumatoid factor (RF), antithyroglobulin (ANTITG), and anti-double stranded DNA (DS-DNA) antibodies were examined. Test results were dichotomized (positive/negative). A subset had autopsy-confirmed neuropathology diagnosis for Alzheimer’s disease neuropathologic change, Lewy body disease, limbic-predominant age related TDP-43 encephalopathy, hippocampal sclerosis (HS), and aging-related tau astrogliopathy. We examined the relationship between neuropathology and antibody positivity using Fischer Chi-Square with Yates’ continuity correction. Results: Of 168 participants with serum results, 44% tested positive for ANA, 31% for ANCA, 21% for RF, 10% for ANTITG, and 6% for DS-DNA antibodies. In the subset with available postmortem results (N=19), antibody positivity rate was similar to the main cohort. Importantly, all participants with hippocampal sclerosis (N=4), were ANA positive and two (50%) had RF antibody. Also the single case with ANTITG antibody had HS. There were no other directions appearing from the other antibody and pathology results. Conclusions: We found that autoantibody positivity rate in an oldest old cohort was much higher than younger cohorts. Increased rate of autoimmunity is a potential explanation for this finding. Furthermore, all individuals with autopsy confirmed HS were ANA positive. In addition, half of HS cases had RF positivity and the only ANTITG positive case had HS. These results raise the possibility of an autoimmune etiology for this common degenerative pathology. Disclosure: Miss Leiby has nothing to disclose. Mr. Ramanathan has nothing to disclose. Ms. Ho has nothing to disclose. Mr. Siguenza has nothing to disclose. Dr. Ahmadi Jazi has nothing to disclose. The institution of Dr. Sajjadi has received research support from NIH.